Is PULMONARY EMBOLISM a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed PULMONARY EMBOLISM.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 85 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported PULMONARY EMBOLISM to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and PULMONARY EMBOLISM. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause PULMONARY EMBOLISM, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes PULMONARY EMBOLISM. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if PULMONARY EMBOLISM ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing PULMONARY EMBOLISM: 85
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where PULMONARY EMBOLISM is a reported side effect: 2.5533%

FDA reports of any drug causing PULMONARY EMBOLISM : 50131
Average percentage for all medicated patients where PULMONARY EMBOLISM is reported as a complication: 0.3142%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
ANGINA PECTORIS ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with PULMONARY EMBOLISM:

YAZ (10468 patients)
YASMIN (9837 patients)
VIOXX (6115 patients)
NUVARING (3058 patients)
ASPIRIN (2569 patients)
DROSPIRENONE AND ETHINYL ESTRADIOL (2329 patients)
ORTHO EVRA (2051 patients)
COUMADIN (1796 patients)
IBUPROFEN (1770 patients)
PREDNISONE (1706 patients)
HEPARIN SODIUM INJECTION (1224 patients)
ALBUTEROL (1222 patients)
DEXAMETHASONE (1211 patients)
ACETAMINOPHEN (1183 patients)
FOSAMAX (1177 patients)
SYNTHROID (1161 patients)
CELEBREX (1134 patients)
OMEPRAZOLE (1125 patients)
HUMIRA (1093 patients)
LASIX (1069 patients)
CISPLATIN (1062 patients)
WARFARIN SODIUM (1052 patients)
METHOTREXATE (1032 patients)
LOVENOX (1019 patients)
NEXIUM (956 patients)
ZOMETA (945 patients)
LEXAPRO (915 patients)
LISINOPRIL (912 patients)
REVLIMID (884 patients)
ZOLOFT (884 patients)
XANAX (880 patients)
FOLIC ACID (878 patients)
FLUOROURACIL (875 patients)
PROTONIX (875 patients)
VICODIN (854 patients)
ATENOLOL (846 patients)
FUROSEMIDE (840 patients)
LIPITOR (825 patients)
HYDROCHLOROTHIAZIDE (806 patients)
LEVOTHYROXINE SODIUM (796 patients)
AMBIEN (792 patients)
LEVAQUIN (785 patients)
PREDNISONE TAB (781 patients)
PERCOCET (774 patients)
PREDNISOLONE (767 patients)
REMICADE (758 patients)
PRILOSEC (749 patients)
LORAZEPAM (739 patients)
DECADRON (737 patients)
PREMARIN (723 patients)
ZOFRAN (722 patients)
SIMVASTATIN (714 patients)
BEXTRA (714 patients)
CYCLOPHOSPHAMIDE (703 patients)
CARBOPLATIN (682 patients)
XARELTO (681 patients)
SEROQUEL (665 patients)
ZYPREXA (663 patients)
MULTI-VITAMIN (661 patients)
OCELLA (653 patients)
MOTRIN (640 patients)
POTASSIUM CHLORIDE (639 patients)
NEURONTIN (636 patients)
AVONEX (634 patients)
SINGULAIR (630 patients)
MORPHINE (621 patients)
ADVAIR DISKUS 100/50 (618 patients)
AVASTIN (596 patients)
HEPARIN (582 patients)
ATIVAN (572 patients)
PREMPRO (569 patients)
METFORMIN HCL (558 patients)
PREVACID (558 patients)
VITAMIN D (548 patients)
ASCORBIC ACID (548 patients)
CAPECITABINE (539 patients)
OXYCODONE HCL (531 patients)
AMOXICILLIN (529 patients)
NAPROXEN (526 patients)
ZYRTEC (512 patients)
LYRICA (507 patients)
ZOCOR (503 patients)
TRAMADOL HCL (494 patients)
OXYCONTIN (494 patients)
ZITHROMAX (485 patients)
BEVACIZUMAB (481 patients)
PRADAXA (472 patients)
LORTAB (472 patients)
EFFEXOR (472 patients)
PROZAC (467 patients)
ENOXAPARIN SODIUM (465 patients)
AZITHROMYCIN (461 patients)
CYMBALTA (460 patients)
MULTI-VITAMINS (454 patients)
LANSOPRAZOLE (450 patients)
TOPROL-XL (449 patients)
NORVASC (447 patients)
ALLOPURINOL (446 patients)
CELEXA (441 patients)
WELLBUTRIN (441 patients)
PLAVIX (440 patients)
FLEXERIL (440 patients)
GABAPENTIN (437 patients)
CLONAZEPAM (431 patients)
TYSABRI (428 patients)
DOXORUBICIN HCL (426 patients)
XELODA (417 patients)
AREDIA (416 patients)
ALPRAZOLAM (415 patients)
TOPAMAX (414 patients)
RISPERDAL (414 patients)
ENBREL (413 patients)
THALOMID (412 patients)
METOPROLOL TARTRATE (412 patients)
CETUXIMAB (409 patients)
CALCIUM (406 patients)
FLUCONAZOLE (405 patients)
DILAUDID (402 patients)
AMLODIPINE (402 patients)
ARIXTRA (400 patients)
NSAID'S (400 patients)
ALLEGRA (395 patients)
FORTEO (393 patients)
OXALIPLATIN (388 patients)
CIPROFLOXACIN (385 patients)
ONDANSETRON (381 patients)
COLACE (380 patients)
ANTIBIOTICS (376 patients)
RITUXIMAB (374 patients)
TYLENOL (CAPLET) (371 patients)
LEUCOVORIN CALCIUM (369 patients)
PAXIL (367 patients)
REGLAN (359 patients)
VITAMIN B-12 (356 patients)
PACLITAXEL (354 patients)
GEMCITABINE (351 patients)
TYLENOL (350 patients)
VINCRISTINE (350 patients)
DIGOXIN (347 patients)
COMPAZINE (346 patients)
TAXOL (343 patients)
FERROUS SULFATE TAB (339 patients)
SPIRONOLACTONE (335 patients)
BENADRYL (335 patients)
PROVERA (328 patients)
TAXOTERE (322 patients)
HYDROCODONE BITARTRATE AND ACETAMINOPHEN (321 patients)
BACTRIM (319 patients)
DIOVAN (317 patients)
RANITIDINE (316 patients)
PANTOPRAZOLE (316 patients)
MORPHINE SULFATE (315 patients)
DOCETAXEL (314 patients)
FLONASE (314 patients)
DIAZEPAM (312 patients)
DURAGESIC-100 (311 patients)
VELCADE (310 patients)
METHYLPREDNISOLONE (309 patients)
ACYCLOVIR (307 patients)
FRAGMIN (306 patients)
CRESTOR (304 patients)
ABILIFY (302 patients)
SPIRIVA (298 patients)
NPLATE (296 patients)
TRAZODONE HCL (295 patients)
CITALOPRAM HYDROBROMIDE (294 patients)
CLARITIN (292 patients)
CALCIUM CARBONATE (291 patients)
RAMIPRIL (290 patients)
FENTANYL (290 patients)
REBIF (290 patients)
ZANTAC (290 patients)
PROMETHAZINE (288 patients)
BACLOFEN (288 patients)
FISH OIL (288 patients)
VALIUM (287 patients)
KEPPRA (285 patients)
GLUCOPHAGE (285 patients)
IRINOTECAN HCL (284 patients)
THALIDOMIDE (280 patients)
ACCUTANE (280 patients)
METOCLOPRAMIDE (279 patients)
SORAFENIB (277 patients)
IMITREX (277 patients)
WARFARIN (275 patients)
DEXAMETHASONE TAB (270 patients)
AMITRIPTYLINE HCL (268 patients)
CEPHALEXIN (268 patients)
PEPCID (265 patients)
IBUPROFEN (ADVIL) (262 patients)
AVELOX (260 patients)
HEPARIN SODIUM (259 patients)
LANTUS (259 patients)
METOPROLOL (257 patients)
AVANDIA (256 patients)
VANCOMYCIN (255 patients)
INSULIN (254 patients)
IRON (254 patients)
CLINDAMYCIN (253 patients)
LOPRESSOR (253 patients)
METRONIDAZOLE (252 patients)
EVISTA (252 patients)
GEMZAR (250 patients)
PANTOPRAZOLE SODIUM (246 patients)
FLUOXETINE (244 patients)
AUGMENTIN '125' (241 patients)
CLOZARIL (235 patients)
MIRTAZAPINE (235 patients)
TEMOZOLOMIDE (235 patients)
INNOHEP (233 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about PULMONARY EMBOLISM and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.